Abstract
We developed a stochastic dynamic transmission model of Monkeypox Virus (hMPXV) to simulate potential spread of hMPXV on a university campus. We used the model to evaluate containment strategies, including detection and isolation of cases and vaccination or quarantine of detected case contacts. We found that detection and isolation of cases was key to containing an outbreak and was able to avert 33%-85% of secondary infections depending on detection rate. Vaccination of known contacts was a useful strategy alongside isolation and detection and could prevent 50% of additional cases. Quarantine was found to have limited benefit.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NIAID of the National Institutes of Health under award number R01AI137093 (VEP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Financial support for this study was also provided by grants from the National Institute on Drug Abuse DP2 (DA049282 to GSG), R37 (DA15612 to AS, GG, and ADP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
